Janux Therapeutics (JANX) | Stock Overview & Key Data
Janux Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $23.89
High: $25.22
on August 22, 2025
52 Week Range
Low: $21.97
High: $71.71
on August 11, 2025
on December 5, 2024
All-Time High: $71.71 on December 2, 2024
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.5B
EPS
-1.81
P/E Ratio (TTM)
-19.24
Forward P/E
-15.96
P/B Ratio
1.53
PEG Ratio
-0.05
Div. Yield
N/A
ROE
-12.82%
Beta
2.852
Debt to Equity
2.24
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
-33,002.05%
Profit Margin
0.00%
Returns and Earnings
Return on Assets (TTM)
-10.51%
Return on Equity (TTM)
-12.82%
EBITDA
$-142.8M
Net Income (TTM)
$-105.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$0.01
Quarterly Revenue Growth (YoY)
N/A
Quarterly Earnings Growth (YoY)
-100.00%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Janux Therapeutics JANX | 1.53B Small-cap | -3.23% | -7.88% | -3.61% | -27.64% | -54.36% | -47.08% | 112.97% | -3.38% |
| Vertex VRTX | 100.19B Large-cap | 0.62% | -15.94% | -8.94% | -17.95% | -2.60% | -17.90% | 40.27% | 46.36% |
| Regeneron REGN | 62.88B Large-cap | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% | -50.84% | -1.12% | -2.18% |
| Cg Oncology CGON | 2.05B Mid-cap | 4.75% | 3.50% | 4.50% | 0.52% | -7.08% | -27.31% | -23.18% | -23.18% |
| Adaptive ADPT | 1.92B Small-cap | -0.31% | 23.46% | 47.06% | 54.39% | 110.02% | 167.70% | 24.14% | -68.12% |
| Vericel VCEL | 1.80B Small-cap | 2.07% | -2.50% | -10.51% | -29.24% | -32.81% | -24.87% | 36.79% | 126.21% |
Ownership & Short Interest
Insider Ownership
6.59%
Institutional Ownership
110.43%
Shares Short
9M
Short Ratio
10.83
Short % of Shares Outstanding
21.29%
Average 10-Day Volume
1M
Average 90-Day Volume
872K
Janux Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Janux Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is JANX's 52-week high and low?
- In the last 52 weeks, Janux Therapeutics reached a high of $71.71 (on December 5, 2024) and a low of $21.97 (on August 11, 2025).
- What is the market cap and P/E ratio for JANX?
- Curious about Janux Therapeutics's size and valuation? Its market capitalization stands at 1.53B. When it comes to valuation, the P/E ratio (trailing twelve months) is -19.24, and the forward P/E (looking ahead) is -15.96.
- Does JANX pay dividends? If so, what's the yield?
- As for dividends, Janux Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Janux Therapeutics's main competitors or similar companies to consider before investing?
When looking at Janux Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.90% 40.27% Regeneron
REGN62.88B Healthcare Biotechnology -50.84% -1.12% Cg Oncology
CGON2.05B Healthcare Biotechnology -27.31% -23.18% Adaptive
ADPT1.92B Healthcare Biotechnology 167.70% 24.14% Vericel
VCEL1.80B Healthcare Biotechnology -24.87% 36.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Janux Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Janux Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -12.82%, the Debt to Equity ratio from the most recent quarter is 2.24, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for JANX?
- Looking at Janux Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $439K. Compared to the same quarter last year (YoY), quarterly revenue grew by N/A, and quarterly earnings saw a YoY growth of -100.00%.
- How much of JANX stock is held by insiders and institutions?
- Wondering who owns Janux Therapeutics stock? Company insiders (like executives and directors) hold about 6.59% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 110.43%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.